Institut National De La Sante Et De La Recherche Medicale

New York Blood Center, Inc.

Genmab A+s

Institut Merieux

Memorial Sloan Kettering Cancer Center

Sloan-Kettering Institute for Cancer Research

Universite Claude Bernard – Lyon1

Hospices Civils De Lyon

Instytut Biochemii I Biofizyki

Instytut Medycyny Doswiadczalnej I Kliniczne

Christian G Trepo

Alfred M Prince

John Vnek

Robert A Neurath

Kyoichi A Watanabe

Carlos A Lopez

Jack J Fox

Genevieve Inchauspe

Anne Fournillier

Christian Reiter

Claude Desgranges

Isabelle Chemin

Francois Habersetzer

Frederic Bedin

Andrzej Lipniacki

Andrzej Piasek

Tadeusz Kulikowski

Maria Bretner

Colette Jolivet Reynaud

Andzelika Najda

Lucyna Cova

Ramamurthy Narayan

Wlodzimierz Zagorski-Ostoja

The invention relates to a non-human primate animal model for HBV infection, said animal model being of the Cercopithecidae family.

Primate model from the family cercopithecidae infected by a HBV strain of human genotype

The present invention relates to novel derivatives of epirubicin, pharmaceutical composition comprising these derivatives, and uses of epirubicin and its derivative for treating HCV.

Derivatives of epirubicin, their medicinal application and pharmaceuticaly acceptable forms of drugs

Described are novel antibodies specifically recognizing conformation dependent epitopes of HCV glycoprotein E2 and that are capable aof neutralizing the binding of E2 protein onto susceptible cells. Furthermore, antigens and epitopes recognized by the above-described antibodies as well as polynucleotides encoding said antibodies are provided. Also provided are to vectors comprising said polynucleotides as well as host cells transformed therewith and their use in the production of said antibodies. In addition, pharmaceutical and diagnostic compositions are provided comprising any of the aforedescribed antibodies, antigens, epitopes, polynucleotides, vectors or cells. Further described is the use of the aforementioned antibodies, antigens, polynucleotides and vectors in adoptive immunotherapy, preferably for the treatment or prevention of HCV infection during liver transplantation.

Anti hepatitis C virus antibody and uses thereof

Isolated HXHV virus having the following characteristics:

HXHV virus, nucleic material, peptide material and uses

The present invention relates to a composition for, and a method of, treating a hepatitis viral infection in a subject using 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil [FEAU].

Method for treating hepatitis B virus infections using

The invention relates to 5-substituted-1-(2'-deoxy-2'-substituted-beta-D-Arabinofuranoysyl) pyrimidine compounds and their use in a method for the treatment of hepatitis B viruses.

Method and composition for hepatitis treatment with pyrimidine

A new vaccine against viral NANB hepatitis containing NANBs antigen in a physiologically acceptable medium. The vaccine is prepared by selecting serums or plasmas in which the presence of NANBs antigens has been identified and thereafter purifying the said antigens. Antibodies are also set forth.

Non-a non-b hepatitis surface antigen useful for the preparation of

A vaccine against viral hepatitis comprising:

Vaccine for active immunization containing hepatitis B surface antigen

A vaccine against viral heptitis comprising:

A process for preparing a vaccine containing unprecipitated filaments and hepatitis B Dane particle specific antigens by removal from a blood serum of other proteinaceous matter such that the serum contains less than 10% proteinaceous matter other than that associated with hepatitis B surface antigen or the filament or Dane particle specific antigen. Any virus present is inactivated, and the antigenous mass is diluted with a physiologically acceptable medium.

Vaccine manufacture for active immunization containing hepatitis B

This invention relates to a medicament which contains a gamma-globulin preparation containing anti-e antibodies. This medicament can be used for eliminating or reducing the infectiousness of biological liquids containing antigen-e or the virus of hepatitis B and can also be administered intramuscularly or intravenously to treat hepatitis and/or acute or chronic infections caused by the virus of hepatitis B in humans and animals.

Growing community of inventors

Bron, France

Christian G Trepo